What are the therapeutic combinations in large cell lymphoma?
In this video, the group discusses adding novel agents to frontline chemotherapy in large B-cell lymphoma, including polatuzumab vedotin with R-CHOP and bispecific
Lymphoma Roundtable
ASH 2025
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Roundtable Discussions
Video Interviews
ASH 2025
Myeloma
Novel protein degraders target myeloma
In this video interview with SOHO Insider, Pan-Yu Chen, PhD, associate director of Translational Medicine at Opna Bio, presents her ASH abstract on
Lymphoma Roundtable
ASH 2025
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
What is the 2025 treatment landscape of follicular lymphoma?
In this video, the panel discusses follicular lymphoma treatment options in 2025.
Multiple Myeloma
News
Society Updates
Facing 2026 with a mix of inspiration and trepidation
"We have so much potential, so many lives dedicated to treatment and prevention of blood cancers, terabytes of data on immune function and
ASH 2025
Myeloproliferative Neoplasms
Primary Myelofibrosis
Adam Mead, MD, on interim phase 1 PROMise trial results in myelofibrosis
In this video interview with SOHO Insider, Adam Mead, MD, professor of hematology at the University of Oxford and lead author on the
ASH 2025
Myelodysplastic Syndromes
Dr. Garcia-Manero presents phase 2 ASTX030 results in MDS and other blood cancers
n this video interview with SOHO Insider, Guillermo García-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes and ad interim chair
ASH 2025
Lymphoma
Aggressive B-Cell Lymphomas
Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL
In this SOHO Insider interview, Pearl van Heteren, MD, medical director in clinical development (Europe) at Miltenyi Biomedicine, discusses the DALY-2 EU trial
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
Golcadomide in the second-line setting in follicular lymphoma
In this video, the group discusses golcadomide's potential in relapsed or refractory follicular lymphoma, including combinations with rituximab in heavily pretreated patients, ongoing
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
How do you approach frontline patients in follicular lymphoma?
In this video, the group discusses approaching frontline follicular lymphoma patients, including determining patients who are high risk using symptoms and disease extent.
Lymphoma Roundtable
Roundtable Discussions
Video Interviews
How do you approach a patient with POD24 in follicular lymphoma?
In this video, the group discusses managing POD24 follicular lymphoma patients, emphasizing clinical trials and preference for T-cell engaging therapies over chemotherapy and